Literature DB >> 33704021

Infection strategies of mycoplasmas: Unraveling the panoply of virulence factors.

Chen Yiwen1, Wu Yueyue1, Qin Lianmei1, Zhu Cuiming1, You Xiaoxing1.   

Abstract

Mycoplasmas, the smallest bacteria lacking a cell wall, can cause various diseases in both humans and animals. Mycoplasmas harbor a variety of virulence factors that enable them to overcome numerous barriers of entry into the host; using accessory proteins, mycoplasma adhesins can bind to the receptors or extracellular matrix of the host cell. Although the host immune system can eradicate the invading mycoplasma in most cases, a few sagacious mycoplasmas employ a series of invasion and immune escape strategies to ensure their continued survival within their hosts. For instance, capsular polysaccharides are crucial for anti-phagocytosis and immunomodulation. Invasive enzymes degrade reactive oxygen species, neutrophil extracellular traps, and immunoglobulins. Biofilm formation is important for establishing a persistent infection. During proliferation, successfully surviving mycoplasmas generate numerous metabolites, including hydrogen peroxide, ammonia and hydrogen sulfide; or secrete various exotoxins, such as community-acquired respiratory distress syndrome toxin, and hemolysins; and express various pathogenic enzymes, all of which have potent toxic effects on host cells. Furthermore, some inherent components of mycoplasmas, such as lipids, membrane lipoproteins, and even mycoplasma-generated superantigens, can exert a significant pathogenic impact on the host cells or the immune system. In this review, we describe the proposed virulence factors in the toolkit of notorious mycoplasmas to better understand the pathogenic features of these bacteria, along with their pathogenic mechanisms.

Entities:  

Keywords:  Mycoplasmas; adhesins; invasive enzymes; metabolites; toxins

Mesh:

Substances:

Year:  2021        PMID: 33704021      PMCID: PMC7954426          DOI: 10.1080/21505594.2021.1889813

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  303 in total

1.  Zinc-binding sites in the N terminus of Mycoplasma arthritidis-derived mitogen permit the dimer formation required for high affinity binding to HLA-DR and for T cell activation.

Authors:  Marc-André Langlois; Youssef El Fakhry; Walid Mourad
Journal:  J Biol Chem       Date:  2003-04-03       Impact factor: 5.157

2.  Biofilm-grown Mycoplasma mycoides subsp. mycoides SC exhibit both phenotypic and genotypic variation compared with planktonic cells.

Authors:  Laura McAuliffe; Roger D Ayling; Richard J Ellis; Robin A J Nicholas
Journal:  Vet Microbiol       Date:  2007-12-04       Impact factor: 3.293

3.  Evolution and function of the Mycoplasma hyopneumoniae peroxiredoxin, a 2-Cys-like enzyme with a single Cys residue.

Authors:  Taylor Gonchoroski; Veridiana G Virginio; Claudia E Thompson; Jéssica A Paes; Cláudio X Machado; Henrique B Ferreira
Journal:  Mol Genet Genomics       Date:  2016-11-17       Impact factor: 3.291

4.  Disruption of the membrane nuclease gene (MBOVPG45_0215) of Mycoplasma bovis greatly reduces cellular nuclease activity.

Authors:  Shukriti Sharma; Kelly A Tivendale; Philip F Markham; Glenn F Browning
Journal:  J Bacteriol       Date:  2015-02-17       Impact factor: 3.490

5.  Mycoplasma bovis escapes bovine neutrophil extracellular traps.

Authors:  Satoshi Gondaira; Hidetoshi Higuchi; Koji Nishi; Hidetomo Iwano; Hajime Nagahata
Journal:  Vet Microbiol       Date:  2016-12-23       Impact factor: 3.293

6.  Identification of biofilm formation by Mycoplasma gallisepticum.

Authors:  Hongjun Chen; Shengqing Yu; Meirong Hu; Xiangan Han; Danqing Chen; Xusheng Qiu; Chan Ding
Journal:  Vet Microbiol       Date:  2012-07-17       Impact factor: 3.293

7.  Characterization of a unique ADP-ribosyltransferase of Mycoplasma penetrans.

Authors:  Coreen Johnson; T R Kannan; Joel B Baseman
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

8.  Extracellular DNA: A Nutritional Trigger of Mycoplasma bovis Cytotoxicity.

Authors:  Xifang Zhu; Emilie Dordet-Frisoni; Lucie Gillard; Abou Ba; Marie-Claude Hygonenq; Eveline Sagné; Laurent Xavier Nouvel; Renaud Maillard; Sébastien Assié; Aizhen Guo; Christine Citti; Eric Baranowski
Journal:  Front Microbiol       Date:  2019-11-29       Impact factor: 5.640

9.  The phospholipid profile of mycoplasmas.

Authors:  Jonathan D Kornspan; Shlomo Rottem
Journal:  J Lipids       Date:  2012-07-15

Review 10.  Inflammation-inducing Factors of Mycoplasma pneumoniae.

Authors:  Takashi Shimizu
Journal:  Front Microbiol       Date:  2016-03-31       Impact factor: 5.640

View more
  5 in total

1.  The first Mycoplasma ovipneumoniae recovered from a sheep with respiratory disease in Brazil - draft genome and genomic analysis.

Authors:  Natália C Gaeta; Ana Marcia de Sá Guimarães; Jorge Timenetsky; Stephanie Clouser; Lilian Gregory; Erika Ganda
Journal:  Vet Res Commun       Date:  2022-07-08       Impact factor: 2.459

Review 2.  Mycoplasmas as Host Pantropic and Specific Pathogens: Clinical Implications, Gene Transfer, Virulence Factors, and Future Perspectives.

Authors:  Ali Dawood; Samah Attia Algharib; Gang Zhao; Tingting Zhu; Mingpu Qi; Kong Delai; Zhiyu Hao; Marawan A Marawan; Ihsanullah Shirani; Aizhen Guo
Journal:  Front Cell Infect Microbiol       Date:  2022-05-13       Impact factor: 6.073

Review 3.  Beware of Mycoplasma Anti-immunoglobulin Strategies.

Authors:  Yonathan Arfi; Carole Lartigue; Pascal Sirand-Pugnet; Alain Blanchard
Journal:  mBio       Date:  2021-11-16       Impact factor: 7.867

Review 4.  The Mycoplasma spp. 'Releasome': A New Concept for a Long-Known Phenomenon.

Authors:  Patrice Gaurivaud; Florence Tardy
Journal:  Front Microbiol       Date:  2022-04-15       Impact factor: 5.640

5.  The expression of GapA and CrmA correlates with the Mycoplasma gallisepticum in vitro infection process in chicken TOCs.

Authors:  Nancy Rüger; Michael P Szostak; Silke Rautenschlein
Journal:  Vet Res       Date:  2022-09-02       Impact factor: 3.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.